JP2006514917A - パーキンソン病および遅発性ジスキネジーの処置のための組成物および方法 - Google Patents

パーキンソン病および遅発性ジスキネジーの処置のための組成物および方法 Download PDF

Info

Publication number
JP2006514917A
JP2006514917A JP2004520071A JP2004520071A JP2006514917A JP 2006514917 A JP2006514917 A JP 2006514917A JP 2004520071 A JP2004520071 A JP 2004520071A JP 2004520071 A JP2004520071 A JP 2004520071A JP 2006514917 A JP2006514917 A JP 2006514917A
Authority
JP
Japan
Prior art keywords
quinoline
amino
composition
diethylamino
butylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004520071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514917A5 (https=
Inventor
ジョディ ネルソン，
Original Assignee
アルファ リサーチ グループ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/192,414 external-priority patent/US20020198231A1/en
Application filed by アルファ リサーチ グループ， エルエルシー filed Critical アルファ リサーチ グループ， エルエルシー
Publication of JP2006514917A publication Critical patent/JP2006514917A/ja
Publication of JP2006514917A5 publication Critical patent/JP2006514917A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004520071A 2002-07-09 2003-07-09 パーキンソン病および遅発性ジスキネジーの処置のための組成物および方法 Pending JP2006514917A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/192,414 US20020198231A1 (en) 1999-07-13 2002-07-09 Compositions and methods for the treatment of Parkinson's disease
US47974803P 2003-06-19 2003-06-19
PCT/US2003/021463 WO2004004660A2 (en) 2002-07-09 2003-07-09 Compositions and methods for the treatment of parkinson’s disease and tardive dyskinesias

Publications (2)

Publication Number Publication Date
JP2006514917A true JP2006514917A (ja) 2006-05-18
JP2006514917A5 JP2006514917A5 (https=) 2006-08-17

Family

ID=30117814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004520071A Pending JP2006514917A (ja) 2002-07-09 2003-07-09 パーキンソン病および遅発性ジスキネジーの処置のための組成物および方法

Country Status (5)

Country Link
EP (1) EP1581167A4 (https=)
JP (1) JP2006514917A (https=)
AU (1) AU2003248893A1 (https=)
CA (1) CA2531810A1 (https=)
WO (1) WO2004004660A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528881A (ja) * 2009-06-03 2012-11-15 マーケット ユニバーシティー 精神障害およびその症状の治療のためのｋｃｎｑカリウムチャネル活性の調節方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
RU2008135762A (ru) * 2006-02-16 2010-03-27 Де МакЛин Хоспитал Корпорейшн (US) Способы и композиции для лечения болезни паркинсона
CN103180297A (zh) * 2009-12-11 2013-06-26 基因密码公司 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法
CN113354581B (zh) * 2020-03-06 2023-06-20 华南理工大学 手性氯喹及其磷酸盐的制备方法及其应用
CN113527201A (zh) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 光学活性氯喹和羟氯喹及其类似物、其制备方法、组合物和用途
WO2025213007A1 (en) * 2024-04-04 2025-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S-hydroxychloroquine, optionally with tauroursodeoxycholic acid and/or 3,3'-diindolylmethane, for treating and/or preventing neurological disorders
CN119924299B (zh) * 2025-04-08 2025-06-06 内蒙古农业大学 羊精子内源铁死亡抑制蛋白保护剂及保护方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428199A1 (de) * 1994-08-09 1996-02-15 Univ Ludwigs Albert Verwendung von Flunitrazepam und/oder Chloroquin zur Behandlung von Spätdyskinesien
WO2001003649A2 (en) * 1999-07-13 2001-01-18 Alpha Research Group, Llc Compositions and methods for the treatment of parkinson's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430039A (en) * 1990-09-28 1995-07-04 Cephalon, Inc. Treatment of neurological disorders
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428199A1 (de) * 1994-08-09 1996-02-15 Univ Ludwigs Albert Verwendung von Flunitrazepam und/oder Chloroquin zur Behandlung von Spätdyskinesien
WO2001003649A2 (en) * 1999-07-13 2001-01-18 Alpha Research Group, Llc Compositions and methods for the treatment of parkinson's disease
JP2004500331A (ja) * 1999-07-13 2004-01-08 アルファ　リサーチ　グループ，　エルエルシー パーキンソン病の処置のための組成物および方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528881A (ja) * 2009-06-03 2012-11-15 マーケット ユニバーシティー 精神障害およびその症状の治療のためのｋｃｎｑカリウムチャネル活性の調節方法
US9017735B2 (en) 2009-06-03 2015-04-28 Marquette University Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof

Also Published As

Publication number Publication date
EP1581167A2 (en) 2005-10-05
EP1581167A4 (en) 2008-10-29
AU2003248893A1 (en) 2004-01-23
WO2004004660A2 (en) 2004-01-15
CA2531810A1 (en) 2004-01-15
AU2003248893A8 (en) 2004-01-23
WO2004004660A3 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
US6417177B1 (en) Chloroquine derivatives for the treatment of Parkinson's disease
Holmquist et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias
TWI519299B (zh) 大麻素與抗精神病藥物組合使用之技術
CN102292094B (zh) 增强神经药方疗效的山梨酸与苯甲酸及其衍生物
US20040229908A1 (en) Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
JP7066627B2 (ja) タンニン酸を含有する組成物及びその使用
JP2023040166A (ja) カンナビジオールによる脆弱ｘ症候群の処置
US20170042878A1 (en) Compositions comprising scopolamine and ketamine in the treatment of depression
JP2010527928A (ja) ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用
US20120034193A1 (en) Treatment of neurotrophic factor mediated disorders
JP2008519847A (ja) 運動障害の治療方法
WO2011019845A1 (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions
US20020198231A1 (en) Compositions and methods for the treatment of Parkinson's disease
JP2006514917A (ja) パーキンソン病および遅発性ジスキネジーの処置のための組成物および方法
Poncin et al. Drug and non-drug treatments of children with ADHD and tic disorders
CN102218091B (zh) 肉桂油、桂皮醛及其衍生物在制备组胺h3受体拮抗剂或反向激动剂药物中的用途
Ciccone Geriatric pharmacology
CN102355902A (zh) 神经营养因子介导的病症的处理
KR20230058615A (ko) 파킨슨병의 운동 합병증 치료약
Sheoran et al. Cerebrovascular pathology and targets for the prevention of Alzheimer's disease
CN115461051A (zh) 药学组合物及其于治疗帕金森氏症的用途
Lewandowska et al. Therapeutic Potential of Dronabinol: A Systematic Review of Human Trials
Horowitz Coenzyme Q10: One antioxidant, many promising applications
KR20010072579A (ko) 우울증 치료 및 그 용도의 약리학적 제제
Silva‐Carvalho et al. Multidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100420